Abstract
Bone metastasis is a frequent complication of lung cancer progression, however, studies on bone metastatic tissues are scanty. Here we have collected a small cohort of 11 non-small cell lung cancer cases where primary tumors and corresponding bone metastases were available for pathological analysis. We have tested two molecular markers: EGFR protein expression and K-RAS mutation at codon 12 using immunohistochemistry and RFLP-PCR, respectively. We have shown that using improved protocols, EGFR protein (both the extracellular as well as the cytoplasmic domain) is readily detectable in decalcified bone tissue. We found that the EGFR expression status is highly similar in bone metastases compared to the primary tumors, although the expression levels may change. Individual comparison of corresponding primary and metastatic NSCLC tissues indicated that downregulation of EGFR was a rare event (2/11) compared to upregulation (4/11) in bone metastases. On the other hand, our data indicate that the K-RAS mutational status of the primary tumor does not predict the status of the bone metastatic tissue of NSCLC, since we have observed both emergence of mutant clones in metastases from wild-type (wt) primary tumors and loss of mutant clones in metastases from mutant primaries in addition to the maintained mutant status. Our data support that at least two progression models occur in NSCLC, the samegene as well as the clonal selection one. It is noteworthy that in NSCLC cases with wtor mutant K-RAS, downregulation of EGFR expression was a rare event although upregulation in bone metastases was observed more frequently in wt K-RAS cases.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593, 2002
Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350:1655–1664, 2004
Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D, Petersen I: Diversity of the gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98:13784–13789, 2001
Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB, Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816–824, 2002
Kopper L, Tímár J: Genomics of lung cancer may change diagnosis, prognosis and therapy. Pathol Oncol Res 11:5–10, 2005
Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F: EGFR mutations in non-smallcell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857–865, 2005
Aviel-Ronen S, Blackhall FH, Shepherd FA, Shepherd FA, Tsao MS: K-ras mutations in non-small cell lung carcinoma: a review. Clin Lung Cancer 8:30–38, 2006
Soung YH, Lee JW, Kim SY, Seo SH, Park WS, Nam SW, Song SY, Han JH, Park CK, Lee JY, Yoo NJ, Lee SH: Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch 446:483–488, 2005
Riely GJ, Politi KA, Miller VA, Pao W: Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12:7232–7241, 2006
Derecskei K, Moldvay J, Bogos K, Tímár J: Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDx™ in paraffin-embedded cancer tissues. Pathol Oncol Res 12: 243–246, 2006
Molina JR, Adjei AA, Jett JR: Advances in chemotherapy of non-small cell lung cancer. Chest 130:1211–1219, 2006
Bepler G, Li X, Sharma A et al: Clinical value of tumoral RRM1 and ERCC1 expressions for treatment response and therapeutic decisions in NSCLC. In: ASCO 2006 Education Book, Ed.: M.C. Perry, ASCO, Alexandria, 2006, pp 431–435
Patel JD: Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. Curr Opin Oncol 18:609–614, 2006
Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759–767, 1990
Gray JW: Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors. Cancer Cell 4:4–6, 2003
Bernards R, Weinberg RA: A progression puzzle. Nature 418:823, 2002
Shiseki M, Kohno T., Nishikawa R, Sameshima Y, Mizoguchi H, Yokota J: Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non small cell lung carcinoma. Cancer Res 54:5643–5648, 1994
Petersen S, Aninat-Mayer M, Schluns K, Gellert K, Dietel M, Petersen I: Chromosomal alteration in the clonal evolution of the metastatic stage of squamous cell carcinoma of the lung. Br J Cancer 82:65–73, 2000
Takahashi K, Kohno T, Matsumoto S, Nakanishi Y, Arai Y, Yamamoto S, Fujiwara T, Tanaka N, Yokota J: Clonal and parallel evolution of primary lung cancers and their metastases revealed by molecular dissection of cancer cells. Clin Cancer Res 13:111–120, 2007
Matsumoto S, Takahasi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, Shimizu E, Yokota J: Frequent EGFR mutation in brain metastases of lung adenocarcinoma. Int J Cancer 15:1491–1494, 2006
Author information
Authors and Affiliations
Corresponding author
Additional information
equalcontribution of the two authors
Rights and permissions
About this article
Cite this article
Badalian, G., Barbai, T., Rásó, E. et al. Phenotype of bone metastases of nonsmall cell lung cancer: Epidermal growth factor receptor expression and KRAS mutational status. Pathol. Oncol. Res. 13, 99–104 (2007). https://doi.org/10.1007/BF02893484
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02893484